Honeywell Survey Reveals Air Travel Passenger Preferences: Frequent Flyers Want More PPE, Technology to Improve Cabin Cleanliness

May 26, 2020

Honeywell notes an informal survey taken by more than 700 frequent business and personal air travel passengers indicates the types of guidelines and health-related equipment passengers may be looking for while flying during and after the COVID-19 pandemic.

The anonymous online survey showed that a majority of travelers (72%) were more concerned with the environment on an airplane than in an airport (28%). Nearly 60% of respondents cited social distancing as their top priority during travel, while about half of respondents cited air quality (51%) and personal protection equipment such as masks (47%) as top priorities. Passengers’ most-desired safety items during travel were masks, hand sanitizer and alcohol wipes.

Cleanliness validation via technology was by far (60%) the most important way to provide confidence in seating-area-related cleanliness, according to the informal survey. Other considerations included providing cleaning supplies directly to the passenger (23%), followed by being informed and updated by the cabin crew (12%).

“This survey demonstrates that passengers want high-tech solutions to best validate the entire travel experience as it relates to health and safety,” said Kevin Suits, vice president, user experience, Honeywell Aerospace. “Honeywell offers a variety of relevant solutions today that we can bring forward to support travelers. We continue to speak with airline executives and transportation leaders about the types of new products and services that would support their efforts to further clean and monitor the cleanliness of their aircraft. We are quickly bringing to market new offerings that would be a win-win for our industry and all of us who love to fly.”

Honeywell notes from an airport perspective, survey respondents were most concerned with the cleanliness of common areas, followed by the ability to social distance and fellow travelers’ use of protective equipment.

This informal and anonymous online survey, captured via SurveyMonkey, had 732 respondents split nearly evenly between North America and Asia, with a small number from elsewhere. The majority, 75%, were ages 25-44. Surveyed travelers fly equally for business and pleasure, mostly on domestic routes.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version